bluuebunny/crossref_metadata_2025_split huggingface dataset:
Biogeographical Distribution of River Microbial Communities in Atlantic Catchments
Authors: Goldenberg‐Vilar Alejandra , Morán‐Luis María , Vieites David R. , Álvarez‐Martínez José Manuel , Silió Ana , Mony Cendrine , Varandas Simone , Monteiro Sandra Mariza , Burgess Diane , Cabecinha Edna , Barquín José 
Published: January 2025

ABSTRACTMicrobes inhabit virtually all river ecosystems, influencing energy flow and playing a key role in global sustainability and climate change. Yet, there is uncertainty about how various taxonomic groups respond to large‐scale factors in river networks. We analysed microbial community richness and composition across six European Atlantic catchments using environmental DNA sequencing. Our findings reveal different drivers for diversity and composition: land use is pivotal for eukaryotes, while climate and geology are crucial for prokaryotes. A strong regional influence shapes these communities, with warmer, drier regions (Portugal and France) differing from cooler, wetter ones (Northern Spain, Ireland and the United Kingdom). These patterns suggest potential indicators for global change, such as taxa resistant to temperature increases and water scarcity, or those sensitive to land use changes.
3D Computed Tomography Reconstruction for Pre‐Operative Diagnosis of Anomalous Venous Drainage of the Right Upper Lobe
Authors: Puca Maria Antonietta , Marella Antonio , Marvulli Maria , Rainone Anna , Capasso Francesca , di Filippo Vincenzo , Messina Gaetana , Fiorelli Alfonso 
Published: January 2025

ABSTRACTAnatomical variation of the pulmonary vessels poses challenges to thoracoscopic lung resection and may be associated with an increased risk of intraoperative bleeding and damage to pulmonary circulation. Herein, we reported a rare and dangerous variation as the partial anomalous venous drainage of the right upper lobe into the superior vena cava in a patient undergoing thoracoscopic lobectomy for management of lung cancer of right upper lobe. The preoperative identification of such variation by 3D computed tomography scan allowed to plan a safe and accurate resection, and to prepare additional strategies for overcome unexpected intraoperative bleeding. No intraoperative and/or postoperative complications were observed. Chest drainage was removed on postoperative day two and patient discharged the day after. At 3 months follow up, the patient was well without recurrence.
The effect of the type of anaesthesia on long‐term outcomes after cancer resection surgery: a narrative review
Authors: Bezu Lucillia , Rahmani Lua S. , Buggy Donal J. 
Published: January 2025

SummaryBackgroundThe peri‐operative period may create a biological environment conducive to cancer cell survival and dissemination. Microscopic residual tumours (micrometastases) can be dislodged even with excellent surgical technique. At the same time, the stress response from surgery can temporarily impair immune function and activate inflammatory processes, increasing the risk of tumour proliferation.MethodsThis narrative review investigates how peri‐operative anaesthetic and analgesic interventions may influence cancer recurrence and metastasis by exploring evidence from both experimental and clinical studies. A comprehensive review of the literature was conducted to identify relevant preclinical and clinical studies published.ResultsWhile surgery remains the best curative option for many cancers, metastasis remains the leading cause of death. Numerous studies have suggested that different anaesthetic drugs and techniques could impact cancer outcomes including volatile anaesthetic agents; total intravenous anaesthesia with propofol; local anaesthetics; regional anaesthesia; and opioids. This review focuses on these five commonly used anaesthetic approaches and evaluates their potential impact on cancer progression.DiscussionThere is a complex interplay between anaesthetic and analgesic techniques and cancer outcomes. Despite promising data from laboratory experimental models, the balance of available clinical trials indicates an equivalent influence of all evaluated anaesthetic techniques on long‐term oncologic outcomes, except, possibly, for peritumoral or intraperitoneal local anaesthetic infiltration.
Systemic anti‐cancer therapy and anaesthesia: a narrative review
Authors: Weaver Jamie M. J. , Patey Susannah J. 
Published: January 2025

SummaryIntroductionCancer research has revolutionised the treatment, quality of life and life expectancy of people living with cancer. Systemic anti‐cancer treatments have expanded to involve not only cytotoxic drugs, but targeted drugs and immunotherapy. Although highly effective in many patients, these drugs can cause serious and sometimes life‐threatening adverse reactions. As part of their treatment, many patients living with cancer will be offered both systemic anti‐cancer therapy and surgery, and many patients will undergo recurrent episodes of both with the aims of cure, palliation or prolongation of life expectancy. It is important for anaesthetists to understand the effects of systemic anti‐cancer therapy on their patients.MethodsAn electronic literature search using was conducted in May 2024 for peer‐reviewed articles in English. An initial search of the terms ‘anaesthesia’ and ‘chemotherapy’ revealed that existing review literature was tailored towards the neoadjuvant setting and prompted this review to include the complications of targeted therapies, emergency care and intra‐operative administration of systemic anti‐cancer therapy to reflect this evolving field. A narrative approach was taken to discuss common regimens and their complications.ResultsThe review encompasses a wide range of sub‐topics including pharmacology; physiology; peri‐operative medicine; specialist surgery; adverse events; and safety. Data from multicentre trials that form the basis of current treatment regimens and practice were prioritised during the selection process. Smaller studies, case series and case reports were included to illustrate the rarer but clinically significant adverse effects of specific therapies.ConclusionsIt is important for anaesthetists to have a comprehensive understanding of the effects of systemic anti‐cancer therapies, including cytotoxic and immunotherapies. There are many potential toxicities and complications associated with these treatments, particularly in the context of emergency surgery and the administration of cytotoxic drugs within the operating theatre environment.
How do women with Rokitansky syndrome and healthcare professionals reflect on the provision of uterine transplantation? Insights from an interview study in France, Norway, and Sweden
Authors: Carton Isis , Dion Ludivine , Lavoué Vincent , Hofmann Bjorn Morten 
Published: January 2025

AbstractIntroductionUterine transplantation is currently intended for women with absolute uterine infertility. Since proof of the concept in 2014, many countries have started research programs and clinical activities. However, access to uterine transplantation remains limited given that only a few hundred transplants have been described worldwide compared with the 1.5 million women of childbearing age who suffer from absolute uterine infertility. The aim of this study was to investigate how limited access to uterine transplantation is perceived by women with Mayer–Rokitansky–Küster–Hauser syndrome and health professionals involved in uterus transplantation programs.Material and MethodsWe conducted a qualitative study with semistructured interviews in France, Norway, and Sweden with women with Mayer–Rokitansky–Küster–Hauser syndrome and health professional involved in uterine transplantation programs. The interviews were analyzed manually using thematic content analysis. The research questions were: How do (a) women with Mayer–Rokitansky–Küster–Hauser syndrome and (b) healthcare professionals involved in uterus transplantation programs perceive uterus transplantation and its accessibility 10 years after proof of concept?ResultsThe interviews enabled us to highlight a number of themes addressed by doctors and women with Mayer–Rokitansky–Küster–Hauser syndrome, the main ones being the hope raised by this technique and the disappointment for those who do not have access to it, the lack of perception of the risks associated with the technique, and finally, an inequity of access and the training difficulties this entails for the teams.ConclusionsAccess to uterine transplantation varies widely across Europe owing to legislative restrictions and limited access due to resources or competence. The result is a feeling of injustice/misunderstanding and despair for these women who had planned to become parents and cannot benefit from a transplant. They appear to be poorly supported. Women who are ultimately unable to access a transplant program should perhaps be given psychological support to deal with this disappointment, whereas the minority who finally have had access to transplant programs are supervised by well‐trained multidisciplinary teams.
Effects of dietary supplementation of myristic acid on jejunal mucosa‐associated microbiota, mucosal immunity, and growth performance of nursery pigs
Authors: Choi Hyunjun , Rocha Gabriel Cipriano , Kim Sung Woo 
Published: January 2025

AbstractThe objective of this study was to investigate the effects of myristic acid on jejunal mucosal microbiota, mucosal immunity, and growth performance of nursery pigs. Thirty‐six pigs (6.6 ± 0.4 kg of body weight) were assigned to three treatments (n = 12) for 35 d in three phases: (NC) basal diet; (PC) NC + bacitracin; and (MA) NC + myristic acid compound. Pigs were euthanized to collect jejunal mucosa, jejunal tissues, and ileal digesta. The PC increased (p < 0.05) the relative abundance (RA) of Lactobacillus spp., and Bifidobacterium boum than the NC group. The MA increased (p < 0.05) RA of Bifidobacterium dentium and Megasphaera spp. than the NC group. The PC tended to decrease IL‐8 (p = 0.053) and protein carbonyl (p = 0.075) whereas IgG (p = 0.051) and IL‐8 (p = 0.090) in jejunal mucosa were decreased by the MA. The PC increased (p < 0.05) the villus height to crypt depth ratio than the NC group. Both bacitracin and myristic acid improved the intestinal health and growth performance of nursery pigs. Effects of bacitracin were rather immediate whereas the effects of myristic acid were obtained after a 3‐week feeding.
Cancer drug applications to the EMA and the FDA: A comparison of new drugs and extension of indication in terms of approval decisions and time in review
Authors: Cramer Allan , Sørup Freja Karuna Hemmingsen , Christensen Hanne Rolighed , Petersen Tonny Studsgaard , Karstoft Kristian 
Published: January 2025

AbstractAimsThe aim of this study was to compare the final approval decision and time from submission to final decision for new drug applications and applications for extension of indications to the EMA and the FDA within cancer drugs.MethodsWe performed a retrospective analysis on antineoplastic drug applications with a final decision in both the EMA and the FDA from January 1, 2018, to December 31, 2022. For each included drug application, we collected data from the EMA website and the Drugs@FDA database.ResultsA total of 48 new drug applications and 94 applications for extension were included. Agreement in the final decision between the EMA and the FDA was found in 94% of new drug applications and 96% of applications for extension. For new drug applications, the time from submission to approval in the EMA and the FDA were median (interquartile range, IQR) 424 (394–481) days and 216 (169–243) days, respectively. For extensions, the median time from submission to approval in the EMA and the FDA were 295 (245–348) days and 176 (140–183) days, respectively.ConclusionsWe found a high agreement in final approval decisions for cancer drug applications between the EMA and the FDA both for new drug applications and applications for extension. The time from submission to the final decision was markedly shorter in the FDA than in the EMA, albeit the difference was smaller for extensions than for new drug applications. The results indicate that the longer time from submission to decision in the EMA than in the FDA has limited influence on the final approval decisions.
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
Authors: Perutelli Francesca , Boccellato Elia , Montalbano Maria Chiara , Catania Gioacchino , Deodato Marina , Frustaci Anna Maria , Innocenti Idanna , Moia Riccardo , Quaglia Francesca Maria , Quaresmini Giulia , Rivela Paolo , Gaidano Gianluca , Krampera Mauro , Laurenti Luca , Rambaldi Alessandro , Bruno Benedetto , Vitale Candida , Coscia Marta 
Published: January 2025

SummaryAllogeneic hematopoietic stem cell transplantation (alloHSCT) remains an option for young and fit chronic lymphocytic leukaemia (CLL) patients with high‐risk disease features. However, allotransplanted patients are generally excluded from clinical trials, making data regarding the use of venetoclax after alloHSCT extremely rare. We report data from 7 CLL patients who received venetoclax after alloHSCT among 53 Italian centers. These patients underwent alloHSCT between 2006 and 2021 after failing chemoimmunotherapy (7/7), ibrutinib (5/7) and/or idelalisib (1/7). Of note, 3/7 patients had already received venetoclax‐based therapy before alloHSCT. Post‐allo HSCT venetoclax treatment resulted safe, with adverse events not different from what reported in clinical trials. Importantly, no meaningful impact on graft versus host disease (GvHD) course was observed: 4/7 patients with pre‐existing chronic GvHD had no exacerbation after venetoclax start, and only one patient developed GvHD during venetoclax therapy, that was managed as per standard clinical practice. Concerning efficacy, 5/7 patients presented a clinical response to venetoclax, with two patients achieving an undetectable minimal residual disease. To our knowledge, this is the largest reported series of CLL patients treated with venetoclax after alloHSCT. In these heavily pretreated and high‐risk patients, previous alloHSCT did not compromise the feasibility of venetoclax therapy, that lacked unexpected toxicities and did not exacerbate GvHD.
Carbonic anhydrase IX inhibition as a path to treat neuroblastoma
Authors: Petrosiute Agne , Zakšauskas Audrius , Lučiūnaitė Asta , Petrauskas Vytautas , Baranauskienė Lina , Kvietkauskaitė Agnė , Ščerbavičienė Alvilė , Tamošiūnaitė Marta , Musvicaitė Justina , Jankūnaitė Alberta , Žvinys Gediminas , Stančaitis Laimonas , Čapkauskaitė Edita , Mickevičiūtė Aurelija , Juozapaitienė Vaida , Dudutienė Virginija , Zubrienė Asta , Grincevičienė Švitrigailė , Bukelskienė Virginija , Schiöth Helgi B. , Matulienė Jurgita , Matulis Daumantas 
Published: January 2025

AbstractBackground and PurposeTumour hypoxia frequently presents a major challenge in the treatment of neuroblastoma (NBL). The neuroblastoma cells produce carbonic anhydrase IX (CA IX), an enzyme crucial for the survival of cancer cells in low‐oxygen environments.Experimental ApproachWe designed and synthesised a novel high‐affinity inhibitor of CA IX. The highest to‐date. The affinities were determined for all human catalytically active CA isozymes showing significant selectivity for CA IX over other isozymes. The inhibitor effect on neuroblastoma cancer cell growth was determined in vitro and in vivo via a mice xenograft model.Key ResultsThe novel designed inhibitor effectively mitigated the acidification induced by CA IX and reduced spheroid growth under hypoxic conditions in the SK‐N‐AS cell line. It also diminished the secretion of pro‐tumour chemokines IL‐8 (CXCL2) and CCL2. When we combined this novel CA IX inhibitor with a compound that inhibits the chemokine receptor CCR2 protein activity, we observed a reduction in mouse tumour growth. The combined treatment also prompted tumours to exhibit adaptive resistance by producing higher levels of vascular endothelial growth factor receptors (VEGFR) and other compensatory signals.Conclusions and ImplicationsThis research underscores the pivotal role of CA IX in cancer and the potential of a novel CA IX inhibitor‐based combination intervention therapy for neuroblastoma treatment.
CYP24A1 Binding to FUS Maintains Tumor Properties by Regulating the miR‐200c/ZEB1/EMT Axis
Authors: Wang Ping , Xu Jiming , You Weijing , Li Jie , Yu Jing , Jiang Fei , Zhang Zengli , Hu Wentao , Li Bingyan 
Published: January 2025

ABSTRACTThe active vitamin D‐degrading enzyme (CYP24A1) is commonly overexpressed in various types of cancer, which is associated with poor prognosis in cancer patients. Recent studies highlight the antagonism of CYP24A1 toward the anticancer role of active vitamin D. However, the impact of CYP24A1 on tumorigenesis and its underlying mechanisms largely remains unexplored. This study also found that high CYP24A1 mRNA expressions were associated with poor prognosis in ovarian cancer and lung adenocarcinoma (LUAD) patients. Moreover, we demonstrated that the overexpression of CYP24A1 accelerated the proliferation, migration, and invasion of ovarian cancer and LUAD cancer cells in vitro. Furthermore, knockdown of CYP24A1 displayed an anticancer effector both in vitro and in vivo. Mechanically, 87–297 amino acid motif of CYP24A1 bound specifically to FUS protein, consequentially reducing FUS affinity for miR‐200c. Considering FUS promotes gene silencing by binding to microRNA targets, a decrease in miR‐200c levels led to a notable activation of its target ZEB1, resulting in the promotion of the epithelial‐mesenchymal transition (EMT) process. In conclusion, FUS binding specifically by CYP24A1 impaired miR‐200c‐mediated ZEB1 silencing, thereby augmenting EMT progression and tumorigenesis. These findings elucidate a fundamental mechanism by which CYP24A1 operates as an oncogene, offering potential targets for therapeutic interventions in cancer treatment.
Enhancing pashmina fabric aesthetics: Assessing the dyeing efficacy of indigenous wild underutilised plants
Authors: Mushtaq Irtizah , Singh Amerjeet , Sofi Asif H. , Sofi P. A. , Khan P. A. , Bhat G. M. , Malik A. R. , Jalal Heena , Jeelani Iqbal , Bilal Tuybia , Benatul‐Behar  , Shabir Sufiya 
Published: January 2025

AbstractThis study explores the use of dyes extracted from Berberis aristata and Bistorta amplexicaulis for dyeing pashmina fabric. The effectiveness of these plant‐derived dyes was evaluated based on colour strength, absorption efficiency and fastness properties including washing, light and rubbing. Results indicate that both Berberis aristata and Bistorta amplexicaulis dyes significantly enhance the colour quality of pashmina fabric, with simultaneous mordanting yielding the highest colour strength and fastness properties, followed by premordanting. Berberis aristata exhibited poor light fastness (1), but showed excellent rubbing and washing fastness (5), while Bistorta amplexicaulis demonstrated good light fastness (4) and (4/5), as well as excellent performance in rubbing and washing fastness (5). Dye concentrations positively impacted colour strength, with higher concentrations resulting in deeper shades. The percentage absorption of the dye into the fabric was notably high, reflecting effective dye uptake. Mordant enhanced the colour quality of the fabric because of the increased efficiency in absorption, colour strength, colour coordinates and fastness grades in terms of washing, light and rubbing, respectively. These findings suggest that dyes from Berberis aristata and Bistorta amplexicaulis are promising for textile applications, offering vibrant, durable colours and adaptable dyeing methods.
White Depressed Areas and Tumor Infiltrating Lymphocytes: The Cancer Cure That Lies Within?
Authors: Murphy George F. 
Published: January 2025

ABSTRACTThis brief overview is inspired by seminal contributions by the late Dr. Martin C. Mihm, Jr. who provided a basis for recognition and better understanding of interactions between lymphocytes (tumor‐infiltrating lymphocytes [TILs]) that home to and permeate cancers. In primary melanomas, this phenomenon may produce what Dr. Mihm called white depressed areas, prescient clues to what would fuel future attempts at harnessing anticancer immunity. The critical and sequential TIL attributes of antigenic stimulation, homing, and effector–target cell apoptotic injury herein are briefly reviewed in light of more recent advances in the field of immuno‐oncology. The intent is to emphasize how fundamental clinical and histopathological observations, as forged by Dr. Mihm and his associates, have led to critically important prognostic paradigms as well as to translational insights that now have become transformative in the field of cancer immunotherapy.
Long‐term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes
Authors: Alkhuzam Khalid , Li Piaopiao , Abuloha Sumaya , Xue Qiaochu , Shi Lizheng , Fonseca Vivian , Zhang Yongkang , Shao Hui 
Published: January 2025

AbstractObjectiveTime in range (TIR) is an important metric to measure variability of blood glucose levels. The aim is to quantify the long‐term health benefits and economic return associated with improved TIR for individuals with type 2 diabetes (T2D).MethodA Markov model with three states (T2D, T2D with cardiovascular disease (CVD) and death) estimated 20‐year medical costs, quality‐adjusted life‐years (QALY) gained and CVD risk under four TIR scenarios: >85%, 71%–85%, 51%–70% and ≤50%. The T2D population was identified using the National Health and Nutrition Examination Survey, and model parameters were sourced from literature. Costs were estimated from a healthcare sector perspective and standardized to 2021 US dollars. Cost ceilings were determined using three willingness‐to‐pay (WTP) thresholds: $100 000/QALY, $50 000/QALY and $0/QALY (cost‐saving).ResultsCompared to TIR <50%, improving TIR to 51%–70% resulted in a 0.79 QALY increase and 4.91% CVD risk reduction; to 71%–85%, a 0.95 QALY increase and 6.24% CVD risk reduction; to >85%, a 1.18 QALY increase and 8.75% CVD risk reduction. To be cost‐effective at $100 000/QALY, annual costs for TIR improvements from <50% to 51%–70%, 71%–85% and >85% should be <$1148, $4200 and $7252, respectively. To be cost‐saving, these costs should be <$612, $2816 and $5021.ConclusionImproving TIR yields significant health benefits. We calculated feasible medical cost allocations for TIR improvements, informing the implementation of interventions like continuous glucose monitoring devices.